MRD and PET response as a new combined clinical endpoint in lymphoma
In the Laboratory Diagnosis Workshop Dr Christiane Pott (University Hospital Schleswig-Holstein, Kiel, Germany) addressed the combination of MRD and PET in follicular lymphoma, based on results of the Gallium trial and the GLSG-Low-Grade NHL trial.
“Achievement and preservation of MRD response is the most important factor for prognosis. MRD and PET response should be integrated into the current response criteria. MRD reappearance can be treated prior to clinical relapse, for example with new drugs in a study context. MRD and PET response allow for early assessment of treatment efficacy and can be used as a new endpoint in clinical studies.”